Adma Biologics reported $28.07M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adamis Pharmaceuticals ADMP:US 9.72M 3.86M
Adma Biologics ADMA:US $ 28.07M 3.5M
Agile Therapeutics AGRX:US $ 28.78M 2.93M
Alnylam Pharmaceuticals ALNY:US $ 657.68M 51.72M
Dynavax Technologies DVAX:US $ 345.2M 121M
Minerva Neurosciences NERV:US $ 3.41M 0.16M
Novavax NVAX:US $ 2156.24M 104.77M
Omeros OMER:US $ 38.5M 3.44M
Takeda 4502:JP Y 2166942M 21212M